Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice

James J. Cray, Seth M. Weinberg, Trish E. Parsons, R. Nicole Howie, Mohammed Elsayed Elsalanty, Jack C Yu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Selective serotonin reuptake inhibitor (SSRI) use in pregnancy has been linked to craniofacial birth defects. Little is known about the effects of serotonin or SSRIs on craniofacial development. Here, we provide evidence that citalopram (SSRI) alters the osteogenic profile of murine calvarial cells and leads to craniofacial dysmorphology. Methods: We used mouse calvarial pre-osteoblast cells (MC3T3-E1) to study the biochemical profile (microarray and quantitative reverse transcription polymerase chain reactions) after treatment with a titrated dose of citalopram. We used C57BL-6 wild-type breeders to produce litters treated with a clinical dose of citalopram during the third trimester of pregnancy. We used micro-computed tomography and morphometric measures to determine effects on craniofacial development. Results: Controls included untreated cells and age matched untreated litters. We observed decreases in proliferation and increases in alkaline phosphatase activity after citalopram exposure. We confirmed altered expression of genes linked to osteogenesis including Ocn and significant increase in expression of Alp after 7 days of treatment. Our data suggest altered expression of several genes related to craniofacial development (Fgf2, Fgfr2, Tgfβr2 Irs1, Igf1) and statistically significant changes in expression for (Col2a1, Gdf6, Hmox1, and Notch1). We also observed changes in regulation of the serotonin pathway (Sert, Tph1, Tph2, Htr2a, Lrp5) after treatment with citalopram. After in utero exposure to citalopram, mice displayed shorter narrow snouts, more globular skulls and several craniofacial anomalies. Conclusion: Our results provide confirmatory evidence that citalopram exposure is associated with cellular and morphological alterations of the craniofacial complex, which may have important implications for use during pregnancy.

Original languageEnglish (US)
Pages (from-to)912-923
Number of pages12
JournalBirth Defects Research Part A - Clinical and Molecular Teratology
Volume100
Issue number12
DOIs
StatePublished - Jan 1 2014

Fingerprint

Citalopram
Serotonin Uptake Inhibitors
Osteoblasts
Gene Expression
Serotonin
Pregnancy
Third Pregnancy Trimester
Osteogenesis
Skull
Reverse Transcription
Alkaline Phosphatase
Tomography
Polymerase Chain Reaction

Keywords

  • Craniosynostosis
  • Depression
  • Osteoblast
  • Osteogenesis
  • SLC6A4 inhibitor
  • Serotonin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Developmental Biology

Cite this

Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice. / Cray, James J.; Weinberg, Seth M.; Parsons, Trish E.; Howie, R. Nicole; Elsalanty, Mohammed Elsayed; Yu, Jack C.

In: Birth Defects Research Part A - Clinical and Molecular Teratology, Vol. 100, No. 12, 01.01.2014, p. 912-923.

Research output: Contribution to journalArticle

@article{f56d64e5cf33468cbb8f96f94c1c8dae,
title = "Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice",
abstract = "Background: Selective serotonin reuptake inhibitor (SSRI) use in pregnancy has been linked to craniofacial birth defects. Little is known about the effects of serotonin or SSRIs on craniofacial development. Here, we provide evidence that citalopram (SSRI) alters the osteogenic profile of murine calvarial cells and leads to craniofacial dysmorphology. Methods: We used mouse calvarial pre-osteoblast cells (MC3T3-E1) to study the biochemical profile (microarray and quantitative reverse transcription polymerase chain reactions) after treatment with a titrated dose of citalopram. We used C57BL-6 wild-type breeders to produce litters treated with a clinical dose of citalopram during the third trimester of pregnancy. We used micro-computed tomography and morphometric measures to determine effects on craniofacial development. Results: Controls included untreated cells and age matched untreated litters. We observed decreases in proliferation and increases in alkaline phosphatase activity after citalopram exposure. We confirmed altered expression of genes linked to osteogenesis including Ocn and significant increase in expression of Alp after 7 days of treatment. Our data suggest altered expression of several genes related to craniofacial development (Fgf2, Fgfr2, Tgfβr2 Irs1, Igf1) and statistically significant changes in expression for (Col2a1, Gdf6, Hmox1, and Notch1). We also observed changes in regulation of the serotonin pathway (Sert, Tph1, Tph2, Htr2a, Lrp5) after treatment with citalopram. After in utero exposure to citalopram, mice displayed shorter narrow snouts, more globular skulls and several craniofacial anomalies. Conclusion: Our results provide confirmatory evidence that citalopram exposure is associated with cellular and morphological alterations of the craniofacial complex, which may have important implications for use during pregnancy.",
keywords = "Craniosynostosis, Depression, Osteoblast, Osteogenesis, SLC6A4 inhibitor, Serotonin",
author = "Cray, {James J.} and Weinberg, {Seth M.} and Parsons, {Trish E.} and Howie, {R. Nicole} and Elsalanty, {Mohammed Elsayed} and Yu, {Jack C}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/bdra.23323",
language = "English (US)",
volume = "100",
pages = "912--923",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitor exposure alters osteoblast gene expression and craniofacial development in mice

AU - Cray, James J.

AU - Weinberg, Seth M.

AU - Parsons, Trish E.

AU - Howie, R. Nicole

AU - Elsalanty, Mohammed Elsayed

AU - Yu, Jack C

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Selective serotonin reuptake inhibitor (SSRI) use in pregnancy has been linked to craniofacial birth defects. Little is known about the effects of serotonin or SSRIs on craniofacial development. Here, we provide evidence that citalopram (SSRI) alters the osteogenic profile of murine calvarial cells and leads to craniofacial dysmorphology. Methods: We used mouse calvarial pre-osteoblast cells (MC3T3-E1) to study the biochemical profile (microarray and quantitative reverse transcription polymerase chain reactions) after treatment with a titrated dose of citalopram. We used C57BL-6 wild-type breeders to produce litters treated with a clinical dose of citalopram during the third trimester of pregnancy. We used micro-computed tomography and morphometric measures to determine effects on craniofacial development. Results: Controls included untreated cells and age matched untreated litters. We observed decreases in proliferation and increases in alkaline phosphatase activity after citalopram exposure. We confirmed altered expression of genes linked to osteogenesis including Ocn and significant increase in expression of Alp after 7 days of treatment. Our data suggest altered expression of several genes related to craniofacial development (Fgf2, Fgfr2, Tgfβr2 Irs1, Igf1) and statistically significant changes in expression for (Col2a1, Gdf6, Hmox1, and Notch1). We also observed changes in regulation of the serotonin pathway (Sert, Tph1, Tph2, Htr2a, Lrp5) after treatment with citalopram. After in utero exposure to citalopram, mice displayed shorter narrow snouts, more globular skulls and several craniofacial anomalies. Conclusion: Our results provide confirmatory evidence that citalopram exposure is associated with cellular and morphological alterations of the craniofacial complex, which may have important implications for use during pregnancy.

AB - Background: Selective serotonin reuptake inhibitor (SSRI) use in pregnancy has been linked to craniofacial birth defects. Little is known about the effects of serotonin or SSRIs on craniofacial development. Here, we provide evidence that citalopram (SSRI) alters the osteogenic profile of murine calvarial cells and leads to craniofacial dysmorphology. Methods: We used mouse calvarial pre-osteoblast cells (MC3T3-E1) to study the biochemical profile (microarray and quantitative reverse transcription polymerase chain reactions) after treatment with a titrated dose of citalopram. We used C57BL-6 wild-type breeders to produce litters treated with a clinical dose of citalopram during the third trimester of pregnancy. We used micro-computed tomography and morphometric measures to determine effects on craniofacial development. Results: Controls included untreated cells and age matched untreated litters. We observed decreases in proliferation and increases in alkaline phosphatase activity after citalopram exposure. We confirmed altered expression of genes linked to osteogenesis including Ocn and significant increase in expression of Alp after 7 days of treatment. Our data suggest altered expression of several genes related to craniofacial development (Fgf2, Fgfr2, Tgfβr2 Irs1, Igf1) and statistically significant changes in expression for (Col2a1, Gdf6, Hmox1, and Notch1). We also observed changes in regulation of the serotonin pathway (Sert, Tph1, Tph2, Htr2a, Lrp5) after treatment with citalopram. After in utero exposure to citalopram, mice displayed shorter narrow snouts, more globular skulls and several craniofacial anomalies. Conclusion: Our results provide confirmatory evidence that citalopram exposure is associated with cellular and morphological alterations of the craniofacial complex, which may have important implications for use during pregnancy.

KW - Craniosynostosis

KW - Depression

KW - Osteoblast

KW - Osteogenesis

KW - SLC6A4 inhibitor

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84919724685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919724685&partnerID=8YFLogxK

U2 - 10.1002/bdra.23323

DO - 10.1002/bdra.23323

M3 - Article

VL - 100

SP - 912

EP - 923

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 12

ER -